Previously reported PDE3A–SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Liu C, Batliwalla F, Li W et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 14(9–10), 575–81 (2008). • This was the first genome-wide association study to investigate biomarkers associated with response to anti-TNF biologics in rheumatoid arthritis.
  Medline CASGoogle Scholar
• 2 Plant D, Bowes J, Potter C et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 63(3), 645–53 (2011). • Genome-wide association study conducted using a UK population of rheumatoid arthritis patients about to commence treatment with/currently receiving anti-TNF biologics.
  Medline CASGoogle Scholar
• 3 Krintel SB, Palermo G, Johansen JS et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet. Genomics 22(8), 577–589 (2012). •• This genome-wide association study was the first to find evidence for association of rs3794271 with response to anti-TNF biologics in a Danish population and was the basis for a replication study conducted by Acosta Colman et al.
  Medline CASGoogle Scholar
• 4 Umicevic MM, Cui J, Vermeulen SH et al. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann. Rheum. Dis. 72(8), 1375–1381 (2013).
  MedlineGoogle Scholar
• 5 Cui J, Stahl EA, Saevarsdottir S et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 9(3), e1003394 (2013).
  Medline CASGoogle Scholar
• 6 Julià A, Fernandez-Nebro A, Blanco F et al. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis. Pharmacogenomics J. 16(2), 147–150 (2016).
  Medline CASGoogle Scholar
• 7 Acosta-Colman I, Palau N, Tornero J et al. GWAS replication study confirms the association of PDE3A–SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 14(7), 727–734 (2013). •• This is the candidate replication study in which rs3794271 successfully replicated in a Spanish cohort of rheumatoid arthritis patients and where upon meta-analysis of both the Danish and Spanish cohorts, the association exceeded genome-wide significance thresholds for association.
  CASGoogle Scholar
• 8 Potter C, Hyrich KL, Tracey A et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann. Rheum. Dis. 68(1), 69–74 (2009).
  Medline CASGoogle Scholar
• 9 Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38(1), 44–48 (1995).
  Medline CASGoogle Scholar
• 10 Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559–575 (2007).
  Medline CASGoogle Scholar
• 11 PLINK (version 1.07) 2007. http://pngu.mgh.harvard.edu/purcell/plink/.
  Google Scholar
• 12 Quanto (version 1.2.4) 2009. http://hydra.usc.edu/gxe.
  Google Scholar
• 13 Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45(12), 1558–1565 (2006).
  Medline CASGoogle Scholar
• 14 van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63(5), 508–516 (2004).
  Medline CASGoogle Scholar
• 15 Wells G, Becker JC, Teng J et al. Validation of the 28-joint Disease activity score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann. Rheum. Dis. 68(6), 954–960 (2009).
  Medline CASGoogle Scholar
• 16 Jurado RL. Why shouldn't we determine the erythrocyte sedimentation rate? Clin. Infect. Dis. 33(4), 548–549 (2001).
  Medline CASGoogle Scholar